Neuropace, Inc. (NPCE) Dividend History

NeuroPace, Inc. (NPCE) is a medical device company specializing in the development and commercialization of responsive neurostimulation systems for the treatment of neurological disorders, primarily epilepsy. Their flagship product, the RNS System, is designed to detect and respond to abnormal brain activity in real-time, aiming to reduce seizure frequency and improve patient quality of life. Founded in 1997, NeuroPace focuses on innovations in neuromodulation technology to address unmet needs in neurological healthcare.

455 N. Bernardo Avenue, Mountain View, CA, 94043
Phone: (650) 237-2700
Website: https://www.neuropace.com

Dividend History

Neuropace, Inc. currently does not pay dividends

Company News

  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

    NeuroPace, Inc. (NPCE) announced that its NAUTILUS study did not reach statistical significance for the primary effectiveness endpoint, causing its stock price to fall 28.39%. Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by the company and its officers.

    GlobeNewswire Inc.
  • Globus Medical (GMED) Q1 Earnings and Revenues Beat Estimates

    Globus Medical (GMED) delivered earnings and revenue surprises of 30.91% and 3.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: GMED
  • The Latest Analyst Ratings For NeuroPace

    Analysts' ratings for NeuroPace (NASDAQ:NPCE) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 2 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 2 0 0 2M Ago 0 1 0 0 0 3M Ago 1 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for NeuroPace, presenting an average target of $16.33, a high estimate of $22.00, and a low estimate of $12.00. Observing a 48.45% increase, the current average has risen from the previous average price target of $11.00. Analyzing Analyst Ratings: A Detailed Breakdown The standing of NeuroPace among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Robbie Marcus JP Morgan Raises Overweight $17.00 $9.00 Ross Osborn Cantor Fitzgerald Raises Overweight $18.00 $16.00 Drew Ranieri Morgan Stanley Raises Equal-Weight $13.00 $9.00 Lawrence Biegelsen Wells Fargo Raises Equal-Weight $16.00 $9.00 Mike Kratky Leerink Partners Announces Outperform $22.00 - Frank Takkinen Lake Street Maintains Buy $12.00 $12.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related ...Full story available on Benzinga.com

    Benzinga
  • NeuroPace, Inc. (NPCE) Q2 2022 Earnings Call Transcript

    NPCE earnings call for the period ending June 30, 2022.

    The Motley Fool
  • Wall Street Breakfast: The Week Ahead

    Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.

    Seeking Alpha
    Featured Companies: AAL AAPL ABT ACI AEP AMZN AN ANTM APH AXP BC BIIB CMG CNI DELL DGX DHR DKNG DOW DV GOOG GOOGL HBAN HON IBM INTC JNJ KMI KRG LRCX LVS LWAY MAT MGTX NFLX NTAP PENN PG PM RAIN RIOT SAM SCL SNAP STT SWIM T TMCI TMO TOST TRV TSLA UAL ULTA VZ WHR
Page data last updated 07/23/2025 17:58:34 UTC